A Phase Ib/IIa trial of Mabwell's anti-ST2 antibody 9MW1911 in 80 former smokers with moderate-to-severe COPD reported an 81% reduction in moderate-to-severe exacerbations and a 100% reduction in severe exacerbations at the 900mg dose, with a clean dose-response relationship. Because each exacerbation removes lung capacity that is not recovered, exacerbation control functions as a determinant of long-term functional reserve. Larger Phase IIb enrollment is complete and Phase III is anticipated around the end of 2026.
Key Points
- Severe COPD exacerbations fell 100% at the 900mg dose
- Anti-ST2 mechanism worked in patients with low eosinophil counts
- Drug exposure scaled with dose; steady state reached by week 12
Longevity Analysis
Respiratory reserve is one of the least forgiving markers of aging — lung function lost to repeated inflammatory injury does not return, and each flare-up narrows the range of what a person can physically do for the rest of their life. Targeting the ST2 pathway addresses inflammatory signaling that appears independent of eosinophil-driven mechanisms, which matters for the substantial patient population that existing biologics do not serve. Interventions that preserve the capacity to breathe and defend against inflammatory escalation extend functional years more reliably than many interventions carrying the longevity label.
Original published by Longevity.Technology, by Kyle Umipig.